

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 74580

Title: Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06253685

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Research Associate

Reviewer's Country/Territory: Poland

Author's Country/Territory: China

Manuscript submission date: 2022-02-17

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-22 08:08

Reviewer performed review: 2022-03-03 09:45

Review time: 9 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

In this retrospective study, the authors analyzed and compared the efficacy, mechanism, and differences between two anti- VEGF drugs (compaq and ranibizumab) in DME patients, to provide a basis for clinical treatment. The experiment of the study is designed very well, aims are very clear. Methods are reasonable. Data in figures and tables are very good, and well discussed. The material studied allows to draw the conclusions. The description of material studied is accurate. I have a minor suggestion: The typical cases in Figures 3 still need to be carefully described in the Results section of the text. Thank you for giving opportunity to review your study.

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 74580

Title: Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06058906

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: United States

Author's Country/Territory: China

Manuscript submission date: 2022-02-17

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-22 08:08

Reviewer performed review: 2022-03-03 09:46

Review time: 9 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

Peer-reviewer statements	Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No
-------------------------------------	---

SPECIFIC COMMENTS TO AUTHORS

I read the manuscript written by Yunfei Li and others with great interest. In my honest opinion, the topic is interesting and the retrospectively studies novel enough to attract the readers' attention. Nevertheless, the authors should clarify some points and improve the discussion citing relevant and novel key articles about the topic. The study is well designed and presented with optimal analysis, discussion, tabulation and graphic display of data. In general, the article provides an essential reference for researchers in this field and the results are interesting and could be useful for other studies.

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 74580

Title: Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06058797

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Spain

Author's Country/Territory: China

Manuscript submission date: 2022-02-17

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-02-22 08:08

Reviewer performed review: 2022-03-03 09:46

Review time: 9 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The article with the title “Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients” is in generally well done. Title: Appropriate. It reflects the main content of the research. Authorship: Is correct. Institutions: are correct. Authors contribution is correct. Abstract: Is a structured abstract according to the required format. In 372 words authors showed a summary of the content of the manuscript. Key words: 6 that reflect the content of the study. Core Tip: In 90 words author reflect properly aspects that should call attention to the readers. Background: It is a retrospective study with a high importance for the clinical practice. Without effective treatment, vision declines rapidly, causing irreversible impairment in DME. Compag has a strong affinity with VEGF receptors, and as a novel VEGF biological agent, it has a relatively strong inhibition of vascular growth in ocular lesions. Investigated the effect and mechanism of anti-VEGF drugs in DME patients is needed in order to improve clinical DME treatment. Results: This study showed that before and 1 mo post-treatment, there was no statistical difference in CMT, SFCT, or FAZ level between the two groups. Three months post-treatment, the estimated values of CMT and SFCT in the compag group were significantly lower than those in the ranibizumab group. Discussion: Authors made a detailed and informative discussion of the results. Illustrations: They show 3 figures and 7 tables with their corresponding legend. All figures and tables are showing clearly making and adequate support of the results. However, I have a little doubt, it didn't find table 6, is it lost? Biostatistics: This work met the requirements of biostatistics. References: Authors cited properly actualized references of high interest for their propose in introduction and discussion Organization

of the study: It was properly organized Research method reporting. As a retrospective study it has been reported according with the corresponding guidelines.